Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06680401
Recruiting Observational

Epithelioid Haemangioendothelioma Observational Study

NCT06680401 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Observational
Started
2021-02-25
Last updated
2026-04-01

Condition(s) studied

Clinical PresentationNatural HistoryTreatment Outcomes

Study summary

The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen * Signed informed consent * Adequate patient compliance to treatment or follow up * No age limit Exclusion Criteria: * Impossibility to ensure adequate compliance

Primary outcome measure(s)

  • Demographic description — Through study completion, an average of 1 year
    To provide a demographic description of the population affected by advanced EHE
  • Patient status — Through study completion, an average of 1 year
    To provide a description of clinical presentation, natural history, and treatment pattern in patients with advanced EHE
  • Tumor-related symptoms — Through study completion, an average of 1 year
    To provide a description of tumour-related symptoms and their changes over time
  • Tumor-related pain — Through study completion, an average of 1 year
    To provide a tumor-related pain assessment
  • Clinical prognosis — Through study completion, an average of 1 year
    To prospectively identify clinical prognostic and predictive factors
  • radiological features — Through study completion, an average of 1 year
    To describe the radiological features of the disease (group A, B, C, D, E)
  • correlation between radiological features and outcome — Through study completion, an average of 1 year
    To correlate radiologic features with the outcome and the tested plasma levels of the cytokines and hormones (group A, B, C, D, E)
  • radiological response and systemic treatment — Through study completion, an average of 1 year
    To assess radiologic response to systemic treatments by basing on RECIST 1.1 assessment (group B, D).

Trial sites (1)

FacilityCityRegionStatus
Fondazione IRCCS IstitutoNazionale dei Tumori Milan Italy Recruiting

More Fondazione IRCCS Istituto Nazionale dei Tumori, Milano trials in Italy

Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma Recruiting
Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer Recruiting
Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare) Active, not recruiting
Study of PembrolizumAb combiNeD With Cisplatin or carbOplatin and Etoposide in Treatment naïve Advanced meRkel Cell cArcinoma (MCC) Starting soon
Revisiting the Concept of Nerve Sparing Radical Hysterectomy Starting soon

Other trials for the same condition

phenotypeS in Non Ambulant Duchenne Muscular Dystrophy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06680401 on ClinicalTrials.gov ↗ ← All trials in Italy